Advanced Accelerator Applications

ICPO Foundation Partners With Leading Pharmaceutical Company to Fund 130 Stipends to Professionals for the Academy's Online Education Program in the Field of Radiomolecular Precision Oncology (RPO) in the Asia Pacific Region.

Retrieved on: 
Thursday, January 18, 2024
Research, Radiology, Pharmaceutical, Philanthropy, Oncology, Training, Other Education, Education, Foundation, Science, Biotechnology, Health, Death, Community, Learning, World Health Organization, Patient, Physics, Hospital, Multimedia, Chemistry, Knowledge, International, Medicine, Novartis, Cancer, ICPO, Advanced Accelerator Applications, Quality of life, Nursing, WHO, RPO, Comprehension

Radiotheranostics has the power to offer novel patient-focused precision oncology treatments according to the principle: “We treat what we see and see what we treat”.

Key Points: 
  • Radiotheranostics has the power to offer novel patient-focused precision oncology treatments according to the principle: “We treat what we see and see what we treat”.
  • Nevertheless, the broad adoption of Radiomolecular Precision Oncology faces substantial hurdles due to a critical shortage of skilled professionals.
  • The ICPO Academy for Theranostics addresses this imperative by offering an extensive online educational program developed by the ICPO Foundation.
  • The primary objective of this program is to disseminate knowledge in Radiomolecular Precision Oncology, thereby improving patient outcomes with radiopharmaceutical therapies.

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

Retrieved on: 
Thursday, December 7, 2023
Advanced Accelerator Applications, External, The, Senior, Head, Third Rock Ventures, Radioligand, Patient, Supply chain, Radiopharmaceutical, BIO, Education minister, Prostate cancer, Biotechnology Innovation Organization, Capital, Supply, Novartis, Drug discovery, Cancer, Growth, RLT, Pharming, Pharmaceutical industry, Management, Daniel

CAMBRIDGE, Mass., OSLO, Norway, LONDON, and BASEL, Switzerland, Dec. 7, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), today announced the closing of an oversubscribed and upsized $90 million Series A financing co-led by Third Rock Ventures and an undisclosed healthcare fund. Additionally, seed lead investors F-Prime Capital and Omega Funds participated substantially. The company's prior seed investment round of $23 million was announced in June 2023.

Key Points: 
  • In these roles, Philippe and Daniel will lead the development and expansion of ARTBIO's unique distributed manufacturing network in support of the company's clinical pipeline.
  • "We are thrilled to have the support of our new and existing investors, including Third Rock Ventures, F-Prime Capital and Omega Funds.
  • These groups bring significant expertise in company scale-up and pipeline development that will be invaluable as we continue to progress our programs and pipeline," said Emanuele Ostuni, Ph.D., CEO of ARTBIO.
  • In Philippe's role as Chief Technical Officer, he will lead the development of ARTBIO's proprietary AlphaDirect™ technology and establishment of the company's distributed manufacturing network.

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

Retrieved on: 
Thursday, December 7, 2023
Advanced Accelerator Applications, External, The, Senior, Head, Third Rock Ventures, Radioligand, Patient, Supply chain, Radiopharmaceutical, BIO, Education minister, Prostate cancer, Biotechnology Innovation Organization, Capital, Supply, Novartis, Drug discovery, Cancer, Growth, RLT, Pharming, Pharmaceutical industry, Management, Daniel

CAMBRIDGE, Mass., OSLO, Norway, LONDON, and BASEL, Switzerland, Dec. 7, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), today announced the closing of an oversubscribed and upsized $90 million Series A financing co-led by Third Rock Ventures and an undisclosed healthcare fund. Additionally, seed lead investors F-Prime Capital and Omega Funds participated substantially. The company's prior seed investment round of $23 million was announced in June 2023.

Key Points: 
  • In these roles, Philippe and Daniel will lead the development and expansion of ARTBIO's unique distributed manufacturing network in support of the company's clinical pipeline.
  • "We are thrilled to have the support of our new and existing investors, including Third Rock Ventures, F-Prime Capital and Omega Funds.
  • These groups bring significant expertise in company scale-up and pipeline development that will be invaluable as we continue to progress our programs and pipeline," said Emanuele Ostuni, Ph.D., CEO of ARTBIO.
  • In Philippe's role as Chief Technical Officer, he will lead the development of ARTBIO's proprietary AlphaDirect™ technology and establishment of the company's distributed manufacturing network.

Ariceum Therapeutics announces granting of US and Canadian patents for its Gallium-68 radiopharmaceutical production kit

Retrieved on: 
Wednesday, December 6, 2023
Acquisition, Advanced Accelerator Applications, Therapy, IP, AAA, Patient, Radiation, Radiopharmaceutical, Prostate cancer, PMSA, PSMA, Diagnosis, Patent, Pharmaceutical industry, Gallium (68Ga) gozetotide

BERLIN, Dec. 6, 2023 /PRNewswire/ -- Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the granting of US and Canadian patents covering its Gallium-68 (Ga-68) radiopharmaceutical production kit.

Key Points: 
  • BERLIN, Dec. 6, 2023 /PRNewswire/ -- Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the granting of US and Canadian patents covering its Gallium-68 (Ga-68) radiopharmaceutical production kit.
  • The IP was developed by Theragnostics Ltd, which was acquired by Ariceum earlier this year.
  • The patents have been sub-licensed exclusively to Advance Accelerator Applications (AAA) and apply to the technology underpinning AAA's Ga-68 HBED-PSMA-11 production kit, branded Locametz®.
  • Theragnostics' Ga-68 technology platform enables the production of multiple doses of Ga-68 HBED-PSMA-11 in a single vial, in one simple step.

Ariceum Therapeutics announces granting of US and Canadian patents for its Gallium-68 radiopharmaceutical production kit

Retrieved on: 
Wednesday, December 6, 2023
Acquisition, Advanced Accelerator Applications, Therapy, IP, AAA, Patient, Radiation, Radiopharmaceutical, Prostate cancer, PMSA, PSMA, Diagnosis, Patent, Pharmaceutical industry, Gallium (68Ga) gozetotide

BERLIN, Dec. 6, 2023 /PRNewswire/ -- Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the granting of US and Canadian patents covering its Gallium-68 (Ga-68) radiopharmaceutical production kit.

Key Points: 
  • BERLIN, Dec. 6, 2023 /PRNewswire/ -- Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the granting of US and Canadian patents covering its Gallium-68 (Ga-68) radiopharmaceutical production kit.
  • The IP was developed by Theragnostics Ltd, which was acquired by Ariceum earlier this year.
  • The patents have been sub-licensed exclusively to Advance Accelerator Applications (AAA) and apply to the technology underpinning AAA's Ga-68 HBED-PSMA-11 production kit, branded Locametz®.
  • Theragnostics' Ga-68 technology platform enables the production of multiple doses of Ga-68 HBED-PSMA-11 in a single vial, in one simple step.

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

Retrieved on: 
Monday, October 9, 2023
Ophthalmology, Patent, European, ADHD, Norepinephrine, Treatment, Polygala, EOP, Phase II, Neurology, FDA, Major depressive disorder, Advanced Accelerator Applications, Map, NET, Norepinephrine transporter, MDD, Pharmaceutical industry, Polaris

FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a Taiwanese patent, Application No. 109130285, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company’s asset ABV-1504 for the treatment of Major Depressive Disorder (MDD). The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment.

Key Points: 
  • 109130285, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company’s asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).
  • The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment.
  • The patent application was submitted to the Taiwan Patent and Trademark Office under the title "Polygala Extract for the Treatment of Major Depressive Disorder."
  • The invention relates to oral administration of the formulation containing a Radix Polygala (Polygala tenuifolia Willd) extract, PDC-1421, as a capsule for treating Major Depressive Disorder.

Nusano Appoints Industry Expert Alexandre Gibim as Chief Operations Officer

Retrieved on: 
Friday, September 15, 2023
Therapy, Senior, Radionuclide, Radiopharmaceutical, USD, Acquisition, Novartis, Patient, Education minister, API, Advanced Accelerator Applications, Prostate cancer, Pharmaceutical industry, Management, Fine chemical

VALENCIA, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO).

Key Points: 
  • VALENCIA, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO).
  • “Alexandre is an exceptional, proven leader with experience overseeing diverse functional teams and driving high growth business units.
  • Bringing his talents to Nusano adds commercial and operational depth to our organization for the benefit of our customers.
  • At Nusano, Gibim will be tasked with scaling the commercial capabilities of the company as its 170,000 square-foot production facility comes online in late 2024 and begins commercial operations Q1 2025.

AKTIS ONCOLOGY EXPANDS SCIENTIFIC ADVISORY BOARD TO ADVANCE PIPELINE OF TARGETED ALPHA RADIOPHARMACEUTICALS

Retrieved on: 
Thursday, June 15, 2023
SAB, Endocrinology, University, United States Air Force Scientific Advisory Board, DRS, Radiopharmaceutical, Doctor of Philosophy, McKinsey & Company, Novartis, AAA, University Hospital Heidelberg, Education minister, R, Research, Advanced Accelerator Applications, Pharmaceutical industry, Ǵermo, Olympiaki Akti, MD

BOSTON, June 15, 2023 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the appointment of Germo Gericke, MD, to its Scientific Advisory Board (SAB). Dr. Gericke joins Drs. Ken Herrmann (SAB Chair), Patrick Baeuerle, Erik Chelius, Johannes Czernin, Gary Glick, and Dane Wittrup on the Aktis SAB in advising the company on scientific and clinical development matters.

Key Points: 
  • BOSTON, June 15, 2023 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the appointment of Germo Gericke, MD, to its Scientific Advisory Board (SAB).
  • Dr. Gericke is a clinical development expert with a special focus on oncology and radiopharmaceuticals.
  • "I'm delighted to welcome Germo to Aktis' SAB," said Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology.
  • "Germo's extensive clinical leadership experience and radiopharmaceutical development expertise will provide valuable insights to Aktis as we advance our pipeline of novel radiopharmaceuticals toward the clinic."

ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023

Retrieved on: 
Thursday, June 15, 2023
Canadian Nuclear Laboratories Research Facilities, Global production network, ITM, Society, Culture, SNMMI, MB, Molecular imaging, Radiochemistry, MBA, Research, Radiopharmaceutical, Future, Nuclear medicine, Novartis, Patient, AAA, Education minister, Lutetium, Gallium, Advanced Accelerator Applications, Therapy, BAMF, Conference, Actinium-225, Management, Pharmaceutical industry, Nursing, McCormick Place, MD

The symposium will take place on June 25, from 6:30 pm to 7:30 pm CST in McCormick Place, Lakeside Center, Room E450b.

Key Points: 
  • The symposium will take place on June 25, from 6:30 pm to 7:30 pm CST in McCormick Place, Lakeside Center, Room E450b.
  • “Particularly as the demand for radiopharmaceuticals continues to grow, we value the opportunity to bring together and share this panel’s expertise and unique insights into the clinical, scientific, and production aspects of theranostics,” commented Steffen Schuster, CEO of ITM.
  • Understanding the interdependencies of these stakeholders will help ensure the value of this critical modality for patients now and well into the future.
  • of Canadian Nuclear Laboratories, an accomplished executive with more than 25 years of broad industry experience and currently focused on further developing CNL’s actinium-225 program.

Benefits of investing in St Kitts and Nevis Sustainable Growth Fund for investors

Retrieved on: 
Wednesday, May 17, 2023
UNESCO, Department of Health and Social Security, Universal health care, Government Investment Unit of Indonesia, Tourism, Dominica citizenship by investment programme, National Housing Corporation, Gender Affairs Advisor to the Chief of Staff, Carbon, Sustainable development, Language, Government, Social change, Ministry, Advanced Accelerator Applications, Hospital, Climate change, Joseph, GDP, Social Security, Child, NHC, United States Secretary of Labor, Growth, ESD, Social, Investment, Saint Kitts and Nevis, Corporatization, Conditional sentence, Sales, Monitoring Education for Sustainable Development, Renewable energy, Life insurance, Nursing, Health insurance, Health, Youth, Basseterre, Ageing, Education

The Sustainable Growth Fund has effectively prepared the twin island state to address climate change issues and respond with environmentally friendly solutions.

Key Points: 
  • The Sustainable Growth Fund has effectively prepared the twin island state to address climate change issues and respond with environmentally friendly solutions.
  • An opportunity to invest in St Kitts and Nevis through the Sustainable Growth Fund investment option will offer businesspeople alternative citizenship.
  • Contributing towards the Sustainable Growth Fund is an opportunity to acquire alternative citizenship with a multitude of benefits.
  • St Kitts and Nevis provide investors with business opportunities in its stable and thriving economy.